Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 5 microgram/actuation; glycopyrronium bromide, quantity: 9 microgram/actuation (equivalent: glycopyrronium, qty 7.2 microgram/actuation) - inhalation, pressurised - excipient ingredients: calcium chloride dihydrate; distearoylphosphatidylcholine; norflurane - maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate, severe, or very severe chronic obstructive pulmonary disease (copd) who require treatment with a combination of an inhaled corticosteroid (ics), a long-acting beta2-agonist (laba), and a long-acting muscarinic antagonist (lama). breztri aerosphere 160/7.2/5 is not indicated for the initiation of therapy in copd.

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aussieguard natural products pty ltd - extract of lemon eucalyptus being acid modified oil of - aerosol - extract of lemon eucalyptus being acid modified oil of extract-plant active 338.0 g/kg - household insecticide - pest control - personal use - black fly | midges & sandflies - culicoides spp. | mosquito - aedes spp. | mosquito - anopheles spp. | mosquito - culex spp. | sand fly (biting midge) | stable fly | tick

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 2.103 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for the prevention of post-operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cefoxitin sodium, quantity: 1.051 g - injection, powder for - excipient ingredients: - cefoxitin sodium for injection is indicated for the treatment of the following infections when due to susceptible organisms (see microbiology): peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, and skin and skin structure infections. cefoxitin sodium for injection has a high degree of stability against beta-lactamase and therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. it can also be used in mixed infections provided that the organisms are sensitive to it. cefoxitin sodium can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes or anaerobes. cefoxitin sodium for injection is also indicated for the prevention of post-operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - tramazoline hydrochloride, quantity: 1.18 mg/ml - spray, solution - excipient ingredients: purified water; dibasic sodium phosphate dihydrate; citric acid monohydrate; sorbitol solution (70 per cent) (non-crystallising); sodium chloride; benzalkonium chloride - symptomatic relief of nasal congestion associated with common cold, hayfever and rhinitis.

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

certis belchim nv - imazalil present as the sulfate; liquid hydrocarbon - aerosol - imazalil present as the sulfate imidazole active 20.0 g/kg; liquid hydrocarbon solvent other 0.0 u - fungicide

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bird healthcare pty ltd - 35122 - inhaler, aerosol, portable - a disposable casing/mouthpiece used to deliver aerosolised medication into a chamber or directly into the mouth of the user.

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - metiram; pyraclostrobin - water dispersible granule - metiram carbamate-dithiocarbamate active 550.0 g/kg; pyraclostrobin carbamate-methoxy active 50.0 g/kg - fungicide - capsicum or pepper | eggplant | mango | pepper | poppy | potato | tomato (except greenhouse) | except greenhouse - anthracnose | downy mildew | early blight | early blight or target blackspot | late blight or irish blight | powdery mildew - oidium spp. | stem end rots | irish blight | target spot

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

swirl technologies pty ltd t/a parker healthcare - 35142 - aerosol face mask, rebreathing - to be placed over the nose and mouth to deliver air, oxygen, or a mixture of the two gases containing aerosol particles to a patient's airway.

Evrópusambandið - enska - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive - formoterol and glycopyrronium bromide - bevespi aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).